Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Depomed Sues Impax, Par in Patent Case Over Gralise Copy

Depomed Inc. sued the generic-drug makers Impax Laboratories Inc. and Par Pharmaceutical Co. to prevent them from selling copies of Gralise, a medicine that treats pain after shingles infections.

Impax and Par are seeking U.S. Food and Drug Administration approval to sell generic versions of Gralise, according to a complaint filed April 10 in federal court in Trenton, New Jersey. Depomed, based in Menlo Park, California, said the copies for 300 and 600 milligram tablets would infringe six patents. It seeks a court order to prevent sales until the patents expire.

Impax, based in Hayward, California, confirmed in a statement today that it filed an FDA application challenging the patents. Allison Wey, a spokeswoman for Par, based in Woodcliff, New Jersey, didn’t immediately return a call seeking comment.

On March 2, Depomed also sued Actavis Group Hf, Watson Pharmaceuticals Inc. and Incepta Pharmaceuticals Co., claiming they infringed the same six Gralise patents.

The case is Depomed Inc. v. Impax Laboratories, 12-cv-2154, U.S. District Court, District of New Jersey (Trenton).

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.